Clin Cancer Res 2012, 18:2039–2047.PubMedCentralPubMedCrossRef 16. Lebbé C, McDermott DF, buy IWP-2 Robert C, Lorigan P, Ottensmeier CH, Wolchok J, Garbe C, Messina M, Hoos A, Weber JS: Ipilimumab improves survival in previously treated advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III

trial. Ann Oncol 2010,21(suppl 8):abstr 13240. 17. Robert C, Ghiringhelli F: What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 2009, 14:848–861.PubMed 18. Lawrence Go6983 nmr D, McDermott D, Hamid O, Weber J, Wolchok J, Richards J, Minor D, Pavlick A, Sznol M, Hwu P, Urba W, Amin A, Bennett K, Michener T, Balogh A, Hodi FS: Treatment of Patients (pts) with Stage III or IV Melanoma on an Ipilimumab (Ipi) Expanded Access Program (EAP): Results for 3 mg/kg Cohort. Hollywood, USA: Society for Melanoma Research (SMR) Congress; 2012. 19. Lawrence D, McDermott

D, Hamid O, Weber J, Wolchok J, Richards J, Amin A, Bennett K, Balogh A, Hodi FS: Ipilimumab (IPI) Expanded Access Program (EAP) for patients AZD6738 (pts) with Stage III/IV melanoma: safety data by subgroups. Ann Oncol 2012,23(suppl Adenosine triphosphate 9):abstr 1129P. 20. Lopez Martin JA, Gonzalez Cao M, Sereno M, Mayordomo J, Hidalgo M, Campos B, Cumplido D, Zambrana F, Medina J, Berrocal A: Ipilimumab in older

patients: Spanish melanoma multidisciplinary group (GEM) experience in the expanded access programme. Ann Oncol 2012,23(suppl 9):abstr 3233. 21. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M: Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014, 50:121–127.PubMedCrossRef 22. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA: Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013, 24:2911–2915.PubMedCrossRef 23. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412–7420.PubMedCrossRef 24.